Ishizuka et al. also propose that anti-PD-1 therapy can be effective without the presence of activated tumor-specific CD8+ T cells when ADAR1 is inhibited, because it produces significant inflammation and reduces tumor size [122]. Here, CD8A is linked to neoplasm.